Duloxetine Delayed-Release Capsules USP — Class II drug recall D-0105-2025
Ongoing recall by Rising Pharma Holding, Inc., reported 2024-12-11, distributed nationwide. CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
| Recall number | D-0105-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Rising Pharma Holding, Inc., East Brunswick, NJ, United States |
| Recall initiated | 2024-11-19 |
| Classified | 2024-12-05 |
| Reported by FDA | 2024-12-11 |
| Distributed | Nationwide (US) |
| Quantity | 209,376 bottles |
| Reason classes | cgmp, specification failure |
| NDC | 57237-0017-60 |
| Lot numbers | DT2022023A, DT2022024A, DT2022025A, DT2022026A, DT2022027A, DT2023001B, DT2023004A, DT2023005A, DT2023006A, JAN-25, NOV-24 |
Product
Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ NDC 57237-017-60
Reason for recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0105-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.